Mitochondria are the parts of your cells that turn food into usable energy. A newer area of research looks at small peptides that are either made from mitochondrial DNA or aimed at mitochondria. MOTS-c is the best known of these online. This post explains MOTS-c, its cousins humanin and SS-31, and how far the evidence really goes.
Key takeaways
- MOTS-c and humanin are "mitochondrial-derived peptides," coded by small stretches of mitochondrial DNA.
- Most MOTS-c research is in mice and cells, where it affected metabolism and exercise capacity. Human evidence is mostly observational blood-level studies.
- MOTS-c is not FDA-approved, and it is banned at all times by WADA.
- SS-31 (elamipretide) is different. It is a lab-designed peptide that targets mitochondria, and it got FDA accelerated approval in 2025 for one rare disease.
- Exercise is still the best-proven way to support mitochondrial health.
What "mitochondrial peptides" means
Mitochondria have their own small set of DNA, separate from the DNA in the cell's nucleus. In the early 2000s and 2010s, researchers found that some short stretches of this mitochondrial DNA can code for small peptides. These were named mitochondrial-derived peptides. MOTS-c and humanin are the two most studied.
SS-31 is not made by mitochondria. It is a synthetic peptide designed to travel into mitochondria and bind to a fat in their inner membrane called cardiolipin. It often gets grouped with the others because of its target.
MOTS-c: what the research shows
MOTS-c is a 16-amino-acid peptide. It was first described in 2015. See our MOTS-c peptide page for a quick profile.
Animal and cell studies
In mice, MOTS-c has been reported to:
- Improve insulin sensitivity and protect against diet-induced weight gain
- Act on AMPK, an energy-sensing pathway also involved in exercise
- Improve physical performance in older mice in some studies
These findings are why it gets labeled an "exercise mimetic." That label goes further than the evidence. Mice are not people, and lab conditions are tightly controlled.
Human studies
Human research so far mostly measures natural MOTS-c levels in the blood and looks for links:
- One study found MOTS-c levels were tied to insulin sensitivity in lean people but not in people with obesity.
- Another looked at MOTS-c levels in women with and without PCOS.
- A 2024 meta-analysis reviewed links between mitochondrial-derived peptides and metabolic health.
Blood-level links do not show that taking MOTS-c helps. We could not find solid randomized human trials showing injected MOTS-c is safe and effective for weight, diabetes or aging.
Humanin
Humanin was discovered in 2001 while researchers studied brain cells in Alzheimer's disease. Lab and animal work suggests it may protect cells under stress. Like MOTS-c, it remains a research peptide with no FDA approval and very little human treatment data. More is on our humanin page.
SS-31 (elamipretide): the one with an approval
On September 19, 2025, FDA granted accelerated approval to elamipretide, brand name Forzinity, as the first treatment for Barth syndrome. Barth syndrome is a rare, life-threatening mitochondrial disease. The approval covers patients who weigh at least 30 kg and was based on improved strength in a thigh muscle. The company must run a confirming trial.
This approval matters, but it is narrow. It does not mean elamipretide is proven for energy, aging or any other condition, and it does not say anything about MOTS-c or humanin. See the SS-31 profile for more.
Side-by-side comparison
| MOTS-c | Humanin | SS-31 (elamipretide) | |
|---|---|---|---|
| Origin | Mitochondrial DNA | Mitochondrial DNA | Lab-designed |
| Main evidence | Mice, cells, human blood-level studies | Cells, animals | Human trials in rare disease |
| FDA status (Oct 2026) | Not approved | Not approved | Accelerated approval for Barth syndrome only |
| WADA | Named, banned at all times | Not named; check before use | Not named; check before use |
Regulatory status of MOTS-c in 2026
In April 2026, FDA said it would remove MOTS-c from Category 2 of its interim compounding lists. In July 2026, the Pharmacy Compounding Advisory Committee voted 7-5, with two abstentions, to recommend adding MOTS-c to the 503A bulks list, against FDA staff's recommendation. The vote is advisory, and FDA must still go through rulemaking. MOTS-c remains an unapproved drug. Our guide to whether peptides are legal explains this process.
For athletes, the 2026 WADA Prohibited List names MOTS-c under metabolic modulators, prohibited at all times.
What helps your mitochondria today
The strongest evidence for better mitochondrial function in people comes from habits:
- Regular aerobic exercise, like brisk walking, cycling or swimming
- Strength training a few times a week
- Good sleep
- Managing blood sugar with your healthcare team
The bottom line
MOTS-c and humanin are exciting research topics, but they are still mostly animal and lab stories, and neither is FDA-approved. SS-31 shows that a mitochondria-targeting peptide can reach approval, but only for one rare disease after years of trials. For everyday energy and healthy aging, exercise remains the proven tool.
Sources
- FDA Grants Accelerated Approval for First Treatment for Barth Syndrome (FDA)
- MOTS-c: A promising mitochondrial-derived peptide for therapeutic exploitation (PMC)
- Plasma MOTS-c levels are associated with insulin sensitivity in lean but not in obese individuals (PubMed)
- FDA Panel Backs 6 Peptides for Compounding (AJMC)
- WADA 2026 Prohibited List, official text (copy hosted by SEGAS)
Frequently asked questions
Is MOTS-c FDA-approved?
No. MOTS-c is not FDA-approved for any condition, and its evidence comes mostly from animal and cell studies. A July 2026 FDA advisory committee vote recommending it for the compounding list was advisory and is not an approval.
Is any mitochondrial peptide FDA-approved?
Yes, one. Elamipretide (SS-31), sold as Forzinity, received FDA accelerated approval in September 2025 for Barth syndrome, a rare mitochondrial disease, in patients weighing at least 30 kg. That approval does not cover general anti-aging or energy uses.
Is MOTS-c banned in sport?
Yes. The 2026 WADA Prohibited List names MOTS-c under S4.4.1 as a metabolic modulator, prohibited at all times. Tested athletes should not use it.